Kratom Group Sharpens Criticism Of 'Opioid' Finding In FDA's Report To DEA
This article was originally published in The Rose Sheet
Executive Summary
American Kratom Association realizes FDA could have significant influence on DEA decision on whether to schedule kratom constituent ingredients as controlled substances. The association and experts on kratom say FDA's, which concluded that mitragynine and 7-hydroxymitragynine are opioids and use of kratom is dangerous, contains numerous inaccuracies and incorrect conclusions.